Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size, Share Global Analysis Report, 2022 – 2030

report img

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size, Share, Growth Analysis Report By End-User (Cancer Treatment Center, Hospitals, and Others), By Drug Type (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocytic Leukemia, Lymphoma, and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030

Industry Insights

[210+ Pages Report] According to the report published by Facts Factors, the global chimeric antigen receptor (CAR) T-Cell therapy market size was worth around USD 1.69 billion in 2021 and is predicted to grow to around USD 6 billion by 2030 with a compound annual growth rate (CAGR) of roughly 13.49% between 2022 and 2030. The report analyzes the global chimeric antigen receptor (CAR) T-Cell therapy market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the chimeric antigen receptor (CAR) T-Cell therapy market.

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

To know more about this report | Request Free Sample Copy

logoMarket Overview

The immunity system in living organisms works by tracking all the essential and common substances found in the body. If there is an addition of the substance that the body does not recognize, it leads to the immunity system attacking it. With this concept, the chimeric antigen receptor (CAR) T-cell therapy works by making the T-cells which are a type of white blood cells to fight cancer cells. This is achieved by modifying the T-cells in the laboratory which is meant to enable them in finding cancer cells and destroying them.

In some studies, CAR T-cell therapy is also called cell-based gene therapy but the main difference is that it involves changing the genes inside the T-cell to help counter cancer cells. The method can be used to treat different types of cancer and even in cases of other treatments that may have proven to be ineffective. In the therapy, T cells taken from the patients are genetically modified in a research facility by adding a gene for a chimeric antigen receptor or CAR.

logoKey Insights

  • As per the analysis shared by our research analyst, the global chimeric antigen receptor (CAR) T-Cell therapy market is estimated to grow annually at a CAGR of around 13.49% over the forecast period (2022-2030)
  • In terms of revenue, the global chimeric antigen receptor (CAR) T-Cell therapy market size was valued at around USD 1.69 billion in 2021 and is projected to reach USD 6 billion, by 2030.
  • The market is projected to grow at a significant rate due to the growing number of cancer patients across the globe
  • Based on drug type segmentation, axicabtagene ciloleucel was predicted to show maximum market share in the year 2021
  • Based on end-user segmentation, cancer treatment center was the leading application in 2021
  • On the basis of region, North America was the leading revenue generator in 2021

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

To know more about this report | Request Free Sample Copy

logo Growth Drivers

  • Growth in the number of cancer patients to propel market demand

The global chimeric antigen receptor (CAR) T-cell therapy market is projected to grow owing to the increasing number of cancer patients across the globe. As per the World Health Organization (WHO), cancer is described as a large group of diseases that can start from an organ in the body and is caused due to the uncontrollable growth in the number of abnormal cells in the body. Cancer is the second leading cause of death observed globally and the number is as high as 9.8 million.

The most common types of cancer in men are liver, stomach, colorectal, prostate, and lung whereas women are more prone to breast, thyroid, cervical, and lung cancer. The disease does not have a completely effective treatment plan as of 2022 however, research for the same is underway and the scientific community remains hopeful. CAR T cell therapy is becoming a popular choice of treatment amongst medical professionals because of the short time required to conduct the entire process. The altered T-cells can be administered in a single infusion and require only 2 weeks of inpatient care unlike the harsh processes involved in other procedures like chemotherapy.

logo Restraints

  • A possible side-effect to restrict market expansion

CAR T-cell therapy, although effective, has various side effects associated with its use. The intensity of the side effects can range from mild to serious and life-threatening. Hence it is important that the professionals handling the treatment are well-experienced and it should only be carried out in authorized treatment centers. As the CAR T-cells multiply, they can let out cytokines which is the possible cause of side effects like breathing issues, chills and high fever, fast heartbeat, feeling dizzy, tiredness, and joint or muscle pain.

logo Opportunities

  • Longer benefits to provide growth opportunities

CAR T-cells are living drugs and not artificially or synthetically created drugs. Studies have concluded that the effect of these drugs on the immunity system can last for a longer duration, unlike other methods in which the cancer relapse time is relatively shorter. This is because the modified T-cells remain in the body and can recognize the cancer cells at any point they come back in the future. For instance, as per a study conducted by the Cancer Institute of New Jersey, out of the patients who received CAR T-cell treatment, 42% of the patients remained in remission after 15 months of undergoing the process.

logo Challenges

  • High cost of treatment to challenge market growth

CAR T-cell therapy is extremely expensive and cannot be afforded by a large section of the low-income group. As per a December 2021 report by the ASH Clinical News, the per-patient cost of the treatment can reach up to USD 1 million. The drugs used in the treatment are high in cost and the management of treatment-induced adverse events can further lead to a rise in the total expense.

logoSegmentation Analysis

The global chimeric antigen receptor (CAR) T-cell therapy market is segmented based on end-user, drug type, indication, and region

Based on the end-user, the global market decisions are cancer treatment centers, hospitals, and others. In 2021, the global market registered the highest growth in cancer treatment centers because of their ability to treat specific cancer cases. In medical events where cancer has crossed a certain level, patients are generally referred to specialists who deal with particular cancer cases only.CAR T-cell therapy is a relatively new technique and should be conducted by experienced professionals. As per data reported by Penn Medicine Lancaster General Health, 9 out of 10 cancer patients who did not respond to any other treatment method than CAR T-cell therapy achieved full remission.

Based on drug type, the global market divisions areaxicabtagene ciloleucel, brexucabtagene autoleucel, tisagenlecleucel, and others. In 2021, axicabtagene was the highest contributor in the global market due to the increased adoption rate of Yescarta, an areaxicabtagene ciloleucel medicine for treating cases of relapsed follicular lymphoma or large B-cell lymphoma. Annually, 6 in 100,000 people are affected by the latter condition.

logoRecent Developments:

  • In April 2022, A new CAR T-cell therapy for the treatment of solid tumors received safe-to-use status at the American Association for Cancer Research annual meeting (2022). It has already shown signs of efficacy
  • In October 2022, a biotech start-up and scholars at University Hospitals (UH) Seidman Cancer Center developed a streamlined way to manufacture CAR T-cells for treatments associated with immunotherapy, within 24 hours

logoReport Scope

Report Attribute

Details

Market Size in 2021

USD 1.69 Billion

Projected Market Size in 2030

USD 6 Billion

CAGR Growth Rate

13.49% CAGR

Base Year

2021

Forecast Years

2022-2030

Key Market Players

Bluebird Inc., Celyad, TrakCel, Juno Therapeutics, Immune Therapeutics, Eureka Therapeutics, Ziopharm Oncology, and others.

Key Segment

By End-User, Drug Type, Indication, and Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logo Regional Analysis

  • North America to lead with the highest CAGR

The global chimeric antigen receptor (CAR) T-cell therapy market is projected to witness the highest growth in North America due to the growing investments in research & development (R&D) of new cancer treatment therapies and associated drugs. Various cancer research organizations in the US are currently at the forefront of the studies to develop new cancer treatments as well a high emphasis on CAR T-cell therapy could lead to higher investments in this segment.

The advanced health infrastructure and research centers allow analysts to make use of state-of-the-art facilities to develop and design new treatment methods as well as deploy more ways of analyzing the impact of the treatment on the patients. Since the cost of the treatment is expensive, it is currently possible only for patients from high-income groups to afford the treatment which could lead to further regional growth. Asia-Pacific could also register a high CAGR due to the growing number of cancer patients.

logo Competitive Analysis

  • Bluebird Inc. 
  • Celyad 
  • TrakCel 
  • Juno Therapeutics 
  • Immune Therapeutics 
  • Eureka Therapeutics 
  • Ziopharm Oncology

The global chimeric antigen receptor (CAR) T-cell therapy market is segmented as follows:

logoBy End-User Segment Analysis

  • Cancer Treatment Center
  • Hospitals
  • Others

logoBy Drug Type Segment Analysis

  • Axicabtagene Ciloleucel
  • Brexucabtagene Autoleucel
  • Tisagenlecleucel
  • Others

logoBy Indication Segment Analysis

  • Acute Lymphocytic Leukemia
  • Lymphoma
  • Others

logoBy Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Table of Content

  1. Chapter 1. Preface
    1. 1.1 Report Description and Scope
  2. 1.2 Research scope
  3. 1.3 Research methodology
    1. 1.3.1 Market Research Type
    2. 1.3.2 Market research methodology
  4. Chapter 2. Executive Summary
    1. 2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, (2022 - 2030) (USD Billion)
  5. 2.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market : snapshot
  6. Chapter 3. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market - Industry Analysis
    1. 3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Market Dynamics
  7. 3.2 Market Drivers
    1. 3.2.1 Growth in the number of cancer patients to propel market demand
    2. 3.2.2 Driver 2
  8. 3.3 Market Restraints
  9. 3.4 Market Opportunities
  10. 3.5 Market Challenges
  11. 3.6 Porter’s Five Forces Analysis
  12. 3.7 Market Attractiveness Analysis
    1. 3.7.1 Market attractiveness analysis By End-User
    2. 3.7.2 Market attractiveness analysis By Drug Type
    3. 3.7.3 Market attractiveness analysis By Indication
  13. Chapter 4. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market- Competitive Landscape
    1. 4.1 Company market share analysis
    2. 4.1.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: company market share, 2021
  14. 4.2 Strategic development
    1. 4.2.1 Acquisitions & mergers
    2. 4.2.2 New Product launches
    3. 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
    4. 4.2.4 Research and development and Regional expansion
  15. 4.3 Price trend analysis
  16. Chapter 5. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market - End-User Analysis
    1. 5.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market overview: By End-User
    2. 5.1.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market share, By End-User, 2021 and 2030
  17. 5.2 Cancer Treatment Center
    1. 5.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Cancer Treatment Center, 2022 - 2030 (USD Billion)
  18. 5.3 Hospitals
    1. 5.3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Hospitals, 2022 - 2030 (USD Billion)
  19. 5.4 Others
    1. 5.4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Others, 2022 - 2030 (USD Billion)
  20. Chapter 6. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market - Drug Type Analysis
    1. 6.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market overview: By Drug Type
    2. 6.1.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market share, By Drug Type, 2021 and 2030
  21. 6.2 Axicabtagene Ciloleucel
    1. 6.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Axicabtagene Ciloleucel, 2022 - 2030 (USD Billion)
  22. 6.3 Brexucabtagene Autoleucel
    1. 6.3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Brexucabtagene Autoleucel, 2022 - 2030 (USD Billion)
  23. 6.4 Tisagenlecleucel
    1. 6.4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Tisagenlecleucel, 2022 - 2030 (USD Billion)
  24. 6.5 Others
    1. 6.5.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Others, 2022 - 2030 (USD Billion)
  25. Chapter 7. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market - Indication Analysis
    1. 7.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market overview: By Indication
    2. 7.1.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market share, By Indication, 2021 and 2030
  26. 7.2 Acute Lymphocytic Leukemia
    1. 7.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Acute Lymphocytic Leukemia, 2022 - 2030 (USD Billion)
  27. 7.3 Lymphoma
    1. 7.3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Lymphoma, 2022 - 2030 (USD Billion)
  28. 7.4 Others
    1. 7.4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Others, 2022 - 2030 (USD Billion)
  29. Chapter 8. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market - Regional Analysis
    1. 8.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Regional Overview
  30. 8.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share, by Region, 2021 & 2030 (USD Billion)
    1. 8.3. North America
    2. 8.3.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion)
      1. 8.3.1.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Country, 2022 - 2030 (USD Billion)
  31. 8.4 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030
    1. 8.4.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030 (USD Billion)
  32. 8.5 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030
    1. 8.5.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030 (USD Billion)
  33. 8.6 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030
    1. 8.6.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030 (USD Billion)
    2. 8.7. Europe
    3. 8.7.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion)
      1. 8.7.1.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Country, 2022 - 2030 (USD Billion)
  34. 8.8 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030
    1. 8.8.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030 (USD Billion)
  35. 8.9 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030
    1. 8.9.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030 (USD Billion)
  36. 8.10 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030
    1. 8.10.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030 (USD Billion)
    2. 8.11. Asia Pacific
    3. 8.11.1 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion)
      1. 8.11.1.1 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Country, 2022 - 2030 (USD Billion)
  37. 8.12 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030
    1. 8.12.1 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030 (USD Billion)
  38. 8.13 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030
    1. 8.13.1 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030 (USD Billion)
  39. 8.14 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030
    1. 8.14.1 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030 (USD Billion)
    2. 8.15. Latin America
    3. 8.15.1 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion)
      1. 8.15.1.1 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Country, 2022 - 2030 (USD Billion)
  40. 8.16 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030
    1. 8.16.1 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030 (USD Billion)
  41. 8.17 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030
    1. 8.17.1 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030 (USD Billion)
  42. 8.18 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030
    1. 8.18.1 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030 (USD Billion)
    2. 8.19. The Middle-East and Africa
    3. 8.19.1 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion)
      1. 8.19.1.1 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Country, 2022 - 2030 (USD Billion)
  43. 8.20 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030
    1. 8.20.1 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by End-User, 2022 - 2030 (USD Billion)
  44. 8.21 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030
    1. 8.21.1 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Drug Type, 2022 - 2030 (USD Billion)
  45. 8.22 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030
    1. 8.22.1 The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Indication, 2022 - 2030 (USD Billion)
  46. Chapter 9. Company Profiles
    1. 9.1 Bluebird Inc.
    2. 9.1.1 Overview
    3. 9.1.2 Financials
    4. 9.1.3 Product Portfolio
    5. 9.1.4 Business Strategy
    6. 9.1.5 Recent Developments
  47. 9.2 Celyad
    1. 9.2.1 Overview
    2. 9.2.2 Financials
    3. 9.2.3 Product Portfolio
    4. 9.2.4 Business Strategy
    5. 9.2.5 Recent Developments
  48. 9.3 TrakCel
    1. 9.3.1 Overview
    2. 9.3.2 Financials
    3. 9.3.3 Product Portfolio
    4. 9.3.4 Business Strategy
    5. 9.3.5 Recent Developments
  49. 9.4 Juno Therapeutics
    1. 9.4.1 Overview
    2. 9.4.2 Financials
    3. 9.4.3 Product Portfolio
    4. 9.4.4 Business Strategy
    5. 9.4.5 Recent Developments
  50. 9.5 Immune Therapeutics
    1. 9.5.1 Overview
    2. 9.5.2 Financials
    3. 9.5.3 Product Portfolio
    4. 9.5.4 Business Strategy
    5. 9.5.5 Recent Developments
  51. 9.6 Eureka Therapeutics
    1. 9.6.1 Overview
    2. 9.6.2 Financials
    3. 9.6.3 Product Portfolio
    4. 9.6.4 Business Strategy
    5. 9.6.5 Recent Developments
  52. 9.7 Ziopharm Oncology
    1. 9.7.1 Overview
    2. 9.7.2 Financials
    3. 9.7.3 Product Portfolio
    4. 9.7.4 Business Strategy
    5. 9.7.5 Recent Developments

    List of Figures

    1. Market research Type 
    2. Market research methodology 
    3. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion) 
    4. Porter’s Five Forces Analysis 
    5. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market attractiveness, By End-User 
    6. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market attractiveness, By Drug Type 
    7. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market attractiveness, By Indication 
    8. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market share by End-User, 2022 and 2030 (USD Billion) 
    9. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Cancer Treatment Center, 2022 - 2030 (USD Billion) 
    10. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Hospitals, 2022 - 2030 (USD Billion) 
    11. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Others, 2022 - 2030 (USD Billion) 
    12. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market share by Drug Type, 2022 and 2030 (USD Billion) 
    13. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Axicabtagene Ciloleucel, 2022 - 2030 (USD Billion) 
    14. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Brexucabtagene Autoleucel, 2022 - 2030 (USD Billion) 
    15. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Tisagenlecleucel, 2022 - 2030 (USD Billion) 
    16. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Others, 2022 - 2030 (USD Billion) 
    17. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market share by Indication, 2022 and 2030 (USD Billion) 
    18. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Acute Lymphocytic Leukemia, 2022 - 2030 (USD Billion) 
    19. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Lymphoma, 2022 - 2030 (USD Billion) 
    20. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Others, 2022 - 2030 (USD Billion) 
    21. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market share, by Region, 2022 and 2030 
    22. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion) 
    23. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion) 
    24. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion) 
    25. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion) 
    26. The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, 2022 - 2030 (USD Billion) 
    

    List of Tables

    1. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Snapshot 
    2. Drivers of the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: impact analysis 
    3. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    4. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    5. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    6. U.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    7. U.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    8. U.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    9. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    10. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    11. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    12. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    13. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    14. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    15. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    16. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    17. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    18. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    19. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    20. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    21. U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    22. U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    23. U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    24. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    25. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    26. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    27. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    28. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    29. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    30. Rest of Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    31. Rest of Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    32. Rest of Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    33. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    34. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    35. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    36. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    37. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    38. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    39. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    40. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    41. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    42. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    43. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    44. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    45. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    46. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    47. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    48. South-East Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    49. South-East Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    50. South-East Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    51. Rest of Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    52. Rest of Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    53. Rest of Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    54. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    55. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    56. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    57. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    58. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    59. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    60. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    61. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    62. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    63. Rest of Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    64. Rest of Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    65. Rest of Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    66. The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    67. The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    68. The Middle-East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    69. GCC Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    70. GCC Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    71. GCC Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    72. South Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    73. South Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    74. South Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    75. Rest of Middle-East Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By End-User, 2022 - 2030 (USD Billion) 
    76. Rest of Middle-East Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Drug Type, 2022 - 2030 (USD Billion) 
    77. Rest of Middle-East Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market revenue, By Indication, 2022 - 2030 (USD Billion) 
    

Industry Major Market Players

  • Bluebird Inc. 
  • Celyad 
  • TrakCel 
  • Juno Therapeutics 
  • Immune Therapeutics 
  • Eureka Therapeutics 
  • Ziopharm Oncology